1 Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. The Lancet. 2015; 386(10003):1546-55.
2 Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: The major impact of China. HEPATOLOGY. 2014; 60(6):2099-108.
3 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load. GASTROENTEROLOGY. 2006; 130(3):678-86.
4 Chang TT, Liaw YF, Wu SS, et al.. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. HEPATOLOGY. 2010; 52(3):886-93.
5 Zoutendijk R, Reijnders JG, Zoulim F, et al.. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. GUT. 2013; 62(5):760-5.
6 van Zonneveld M, Honkoop P, Hansen BE, et al.. Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B. HEPATOLOGY. 2004; 39(3
):804-10.
7 Lin SM, Yu ML, Lee CM, et al.. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J HEPATOL. 2007; 46(1):45-52.
8 Liaw YF, Kao JH, Piratvisuth T, et al.. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. HEPATOL INT. 2012; 6(3):531-61.
9 EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J HEPATOL. 2012; 57(1):167-85.
10 Chuang WL, Jia J, Chan HLY, et al.. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. ALIMENT PHARM THER. 2018; 47(9):1306-16.
11 Li SY, Li H, Xiong YL, et al.. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J VIRAL HEPATITIS. 2017; 24:12-20.
12 Lau G, Piratvisuth T, Luo KX, et al.. Durability of response and occurrence of late response to peginterferon alpha-2a (40KD)[PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B. J HEPATOL. 2006; 44:S23-4.
13 Wenhong Z, Dazhi Z, Xiaoguang D, Qing X, Jiaji J, Xinyue C. Consensus on pegylated interferon alpha in treatment of chronic hepatitis B. Chin J Hepatol. 2017(9):678-86.
14 Lampertico P, Agarwal K, Berg T, et al.. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J HEPATOL. 2017; 67(2):370-98.
15 Marcellin P, Bonino F, Yurdaydin C, et al.. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. HEPATOL INT. 2013; 7(1):88-97.
16 Moucari R, Mackiewicz V, Lada O, et al.. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. HEPATOLOGY. 2009; 49(4):1151-7.
17 Sonneveld MJ, Hansen BE, Piratvisuth T, et al.. Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels. HEPATOLOGY. 2013; 58(3
):872-80.
18 Piratvisuth T, Marcellin P, Popescu M, Kapprell H, Rothe V, Lu Z. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. HEPATOL INT. 2013; 7(2
):429-36.
19 Sun J, Ma H, Xie Q, et al.. Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. J HEPATOL. 2016; 65(4):674-82.
20 Chen G. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients. WORLD J GASTROENTERO. 2014; 20(25):8195.
21 Brunetto MR, Moriconi F, Bonino F, et al.. Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B. HEPATOLOGY. 2009; 49(4):1141-50.
22 Buster EHCJ, Hansen BE, Lau GKK, et al.. Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa. GASTROENTEROLOGY. 2009; 137(6
):2002-9.
23 Wang Y, Yang S, Su C, et al.. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. SCI REP-UK. 2016; 6(1).
24 Lampertico P, Del Ninno E, Viganò M, et al.. Long-Term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. HEPATOLOGY. 2003; 37(4
):756-63.
25 Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. AM J GASTROENTEROL. 2007; 102(12):2718-23.
26 Yao C, Hung C, Hu T, et al.. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. SCI REP-UK. 2017; 7(1).
27 Cao J, Chi H, Yu T, et al.. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. The Journal of Infectious Diseases. 2017; 215(4):581-9.
28 Hsu YC, Mo LR, Chang CY, et al.. Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients. Clin Gastroenterol Hepatol. 2016; 14(10):1490-8.